1Departments of Medicine, USA
2Departments of Pathology, USA
*Corresponding author: Kieber Emmons T, Departments of Pathology, USA
Submission: May 07, 2019Published: May 16, 2019
Breast cancer is a heterogeneous disease with biological subtypes having different prognostic impacts. This facet is particularly evident in Neoadjuvant trials where Pathological Complete Response (pCR) rates vary. Studies have shown that patients who achieve pCR after neoadjuvant treatment have a better long-term outcome. Consequently, increasing the rate of pCR became the end point of neoadjuvant trials with the expectation of translation into improved survival. However, for Luminal A subtype patients this is not the case, as this cohort does not respond to chemotherapy. Here we consider why this might be the case and several approaches that could change the paradigm treating this cohort.